title: Oxazolone-induced contact hypersensitivity reduces lymphatic drainage but enhances the induction of adaptive immunity.
abstract: Contact hypersensitivity (CHS) induced by topical application of haptens is a commonly used model to study dermal inflammatory responses in mice. Several recent studies have indicated that CHS-induced skin inflammation triggers lymphangiogenesis but may negatively impact the immune-function of lymphatic vessels, namely fluid drainage and dendritic cell (DC) migration to draining lymph nodes (dLNs). On the other hand, haptens have been shown to exert immune-stimulatory activity by inducing DC maturation. In this study we investigated how the presence of pre-established CHS-induced skin inflammation affects the induction of adaptive immunity in dLNs. Using a mouse model of oxazolone-induced skin inflammation we observed that lymphatic drainage was reduced and DC migration from skin to dLNs was partially compromised. At the same time, a significantly stronger adaptive immune response towards ovalbumin (OVA) was induced when immunization had occurred in CHS-inflamed skin as compared to uninflamed control skin. In fact, immunization with sterile OVA in CHS-inflamed skin evoked a delayed-type hypersensitivity (DTH) response comparable to the one induced by conventional immunization with OVA and adjuvant in uninflamed skin. Striking phenotypic and functional differences were observed when comparing DCs from LNs draining uninflamed or CHS-inflamed skin. DCs from LNs draining CHS-inflamed skin expressed higher levels of co-stimulatory molecules and MHC molecules, produced higher levels of the interleukin-12/23 p40 subunit (IL-12/23-p40) and more potently induced T cell activation in vitro. Immunization experiments revealed that blockade of IL-12/23-p40 during the priming phase partially reverted the CHS-induced enhancement of the adaptive immune response. Collectively, our findings indicate that CHS-induced skin inflammation generates an overall immune-stimulatory milieu, which outweighs the potentially suppressive effect of reduced lymphatic vessel function.
authors.affiliation: Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland.
authors.forename: David
authors.initials: D
authors.lastname: Aebischer
authors.affiliation: Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland.
authors.forename: Ann-Helen
authors.initials: AH
authors.lastname: Willrodt
authors.affiliation: Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland.
authors.forename: Cornelia
authors.initials: C
authors.lastname: Halin
mesh_terms: D056704:Adaptive Immunity; D000276:Adjuvants, Immunologic / Q000009:adverse effects; D000818:Animals; D002465:Cell Movement / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D003877:Dermatitis, Contact / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D004195:Disease Models, Animal; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000378:metabolism; D008198:Lymph Nodes / Q000276:immunology*; D042583:Lymphangiogenesis / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008822:Mice, Transgenic; D010081:Oxazolone / Q000009:adverse effects; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D042461:Vascular Endothelial Growth Factor A; D010081:Oxazolone; D018664:Interleukin-12